TLSI (TriSalus Life Sciences) Total Stockholders Equity: $12.81 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TLSI TriSalus Life Sciences Inc TLSI
29 GF Score
Price $4.30
GF Value $4.30
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is TriSalus Life Sciences Total Stockholders Equity?

TriSalus Life Sciences TLSI -1.38% 29 Total Stockholders Equity is $12.81 Mil as of Mar. 2026. GuruFocus rates TLSI with a GF Score™ of 29/100 and a GF Value™ of $4.30 (Fairly Valued). The stock has 5 warning signs investors should review.

TriSalus Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $12.81 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. TriSalus Life Sciences's Book Value per Share for the quarter that ended in Mar. 2026 was $0.21. The ratio of a company's debt over equity can be used to measure how leveraged this company is. TriSalus Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2026 was 2.69.

TriSalus Life Sciences  (NAS:TLSI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

TriSalus Life Sciences's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(12.807-0)/61.414
=0.21

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

TriSalus Life Sciences's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.218 + 34.269) / 12.807
=2.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences Total Stockholders Equity Related Terms

TriSalus Life Sciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for TriSalus Life Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TriSalus Life Sciences Total Stockholders Equity Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
-129.60 -176.33 -27.07 -25.89 -33.86

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.37 -19.42 -26.73 -33.86 12.81
TLSI
29GF Score
TriSalus Life Sciences Inc TLSI
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $12.81 Mil mean?
TriSalus Life Sciences (TLSI) has a Total Stockholders Equity of $12.81 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for TriSalus Life Sciences and its competitors.
Is TriSalus Life Sciences' Total Stockholders Equity too high?
TriSalus Life Sciences' current Total Stockholders Equity is $12.81 Mil. Overall, TriSalus Life Sciences has a GF Score™ of 29/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TriSalus Life Sciences' Total Stockholders Equity compare to TMCI and LAB?
TriSalus Life Sciences' Total Stockholders Equity of $12.81 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for TriSalus Life Sciences and its competitors. TriSalus Life Sciences's current Total Stockholders Equity is $12.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TriSalus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, TriSalus Life Sciences (TLSI) is currently considered Fairly Valued. The stock's GF Value™ is $4.30, compared to a current price of $4.30 — trading right at its estimated fair value. The current Total Stockholders Equity is $12.81 Mil. TriSalus Life Sciences' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For TriSalus Life Sciences (TLSI), the current Total Stockholders Equity is $12.81 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TriSalus Life Sciences (TLSI) Overvalued in 2026?

Based on GuruFocus' analysis, TriSalus Life Sciences stock appears to be undervalued. The current stock price of $4.30 is trading 0% below its estimated GF Value™ of $4.30. GuruFocus considers TriSalus Life Sciences to be Fairly Valued.

Key valuation signals for TLSI:

  • Total Stockholders Equity: $12.81 Mil
  • GF Value™: $4.30 vs. price of $4.30 (0% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the TLSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TriSalus Life Sciences Business Description

Address 6272 W. 91st Avenue, Westminster, CO, USA, 80031
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.
29GF Score

Get the complete analysis for TLSI

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.30
Price
$4.30
GF Value